🔎 Trials Near Me

Home › Non-Hodgkin Lymphoma › Nebraska

Pag-aaral pangklinika para sa Non-Hodgkin Lymphoma sa Nebraska

15 pag-aaral para sa Non-Hodgkin Lymphoma ang naghahanap ng mga kalahok sa mga site sa Nebraska.

Mga Lungsod sa Nebraska

Opisyal na teksto ng pag-aaral (English)

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

  • University of Nebraska Medical Center, Omaha
Nagre-recruitPhase 2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT02693535

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

  • The University of Nebraska Medical Center, Omaha
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07195916

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

  • Local Institution - 0124, Omaha
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06090539

Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

  • Nebraska Cancer Specialists, Omaha
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT06806033

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • University of Nebraska Medical Center, Omaha
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • University of Nebraska Medical Center, Omaha
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06528301

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • University of Nebraska Medical Center (UNMC), Omaha
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Nebraska Medical Center, Omaha
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Halt Aging in Survivors of Blood Cancers

  • University of Nebraska Medical Center, Omaha
Nagre-recruit
Edad 50 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT07292272

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  • Nebraska Cancer Specialists, Omaha
  • University of Nebraska Medical Center, Omaha
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT04068597

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Fred and Pamela Buffett Cancer Center, Omaha
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT03328078

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  • CHI Health Good Samaritan, Kearney
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

  • University Of Nebraska Medical Center, Omaha
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 2, 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

  • University Of Nebraska Medical Center, Omaha
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 2, 2026 · NCT06876649

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.